Elective Microaxial Flow Pump Does Not Improve High-Risk PCI Outcomes

Mechanical Support Strategies in High-Risk Coronary Revascularization

Managing patients with severe left ventricular systolic dysfunction and multivessel coronary artery disease presents a significant challenge for the heart team, particularly when surgical revascularization is deemed too high-risk [1]. Percutaneous coronary intervention in this cohort carries a substantial risk of periprocedural hemodynamic collapse and incomplete revascularization [2]. To mitigate these risks, clinicians have increasingly adopted the use of percutaneous left ventricular assist devices, such as microaxial flow pumps, to provide active hemodynamic support [3, 4]. While these devices are well established for managing cardiogenic shock, their utility as an elective prophylactic measure during stable but complex procedures remains a subject of intense clinical debate [5]. A recent large-scale randomized controlled trial now provides definitive data on whether this strategy improves long-term patient survival and clinical stability, offering critical guidance for interventional cardiologists weighing the risks and benefits of prophylactic mechanical support.

Trial Design and Patient Selection

The CHIP-BCIS3 trial (ClinicalTrials.gov number NCT05003817) was designed to evaluate the efficacy of routine mechanical support in a high-risk population often excluded from traditional revascularization studies. The study randomly assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease to one of two treatment strategies. To ensure a balanced comparison, the researchers utilized a 1:1 ratio for enrollment, specifically targeting individuals whose impaired cardiac function and complex coronary anatomy made them vulnerable to hemodynamic instability during percutaneous revascularization. Within this cohort, 148 patients were assigned to receive elective unloading with a microaxial flow pump, a catheter-based device that actively pumps blood from the left ventricle into the aorta to reduce cardiac workload and maintain systemic perfusion, during their planned complex percutaneous coronary intervention. In the control arm, 152 patients were assigned to receive standard care during their procedure, which relied on conventional hemodynamic management without routine prophylactic mechanical support. This multicenter investigation was funded by the U.K. National Institute for Health and Care Research, providing a rigorous framework to assess whether the added complexity and cost of elective mechanical unloading translate into superior clinical outcomes for this vulnerable patient population.

Primary Composite Endpoint and Statistical Methodology

To evaluate the efficacy of elective mechanical unloading, the researchers utilized a hierarchical composite primary outcome that prioritized the most severe clinical events. This composite endpoint included death from any cause, disabling stroke, spontaneous myocardial infarction, hospitalization for cardiovascular causes, or periprocedural myocardial injury. By grouping these diverse clinical events, the study aimed to capture the full spectrum of risks associated with high-risk percutaneous coronary intervention, ranging from immediate procedural complications to long-term mortality and morbidity. The primary outcome was analyzed at a minimum of 12 months using a win ratio, a statistical method that prioritizes the most clinically significant events in a composite endpoint by comparing pairs of patients. In this analysis, a patient from the microaxial flow pump group is compared to a patient from the standard care group. The pair wins for the strategy that avoids the more severe event, starting with death and moving down the hierarchy to periprocedural injury. For the practicing clinician, this approach ensures that a reduction in mortality carries more weight than a reduction in minor enzymatic elevations, preventing trivial outcomes from skewing the overall results. The researchers followed the study participants for a median period of 22 months, with an interquartile range of 16 to 30 months, providing a robust window to observe both early procedural outcomes and late-term cardiovascular stability.

Clinical Outcomes and Mortality Trends

The primary outcome analysis revealed that elective mechanical unloading did not provide a clinical advantage over standard care. In the hierarchical composite analysis, 36.6% of pairwise comparisons favored the microaxial flow pump, while 43.0% favored standard care. This resulted in a win ratio of 0.85 (with a 95% confidence interval of 0.63 to 1.15). The difference in pairwise comparisons was -6.4 percentage points, indicating a clear lack of superiority for the device strategy. With a P value of 0.30, the findings demonstrated no statistically significant difference between the two treatment arms regarding the primary composite endpoint. Furthermore, survival data raised critical questions regarding the routine use of these devices in stable high-risk percutaneous coronary intervention. Death from any cause occurred in 47 patients in the microaxial-flow-pump group, compared to 33 patients in the standard-care group. This distribution of mortality resulted in a hazard ratio for death from any cause of 1.54, with a 95% confidence interval of 0.99 to 2.41. Although the confidence interval slightly crossed 1.0, making the finding statistically non-significant, the numerical increase in deaths within the pump group suggests that the routine application of mechanical unloading fails to improve outcomes and could potentially correlate with an increased risk of mortality in this specific clinical context.

Safety Profile and Procedural Complications

Beyond the primary efficacy endpoints and mortality trends, the researchers conducted a detailed assessment of procedural safety to determine if the use of a microaxial flow pump introduced additional iatrogenic risks. Despite the requirement for large-bore arterial access to accommodate the device, the study found that there was no material between-group difference in the risk of bleeding or vascular complications. This finding suggests that while the device did not provide a clear clinical benefit, its elective implementation did not significantly increase the incidence of immediate procedural harm compared to standard care in this high-risk cohort. Ultimately, the cumulative evidence from this trial indicates that elective left ventricular unloading with a microaxial flow pump did not reduce the risk of major adverse clinical outcomes at a minimum of 12 months among patients with severely impaired left ventricular function undergoing complex percutaneous coronary intervention. For the practicing interventional cardiologist, these results underscore the importance of selective rather than routine use of mechanical support. Given the lack of improvement in the primary composite outcome and the concerning numerical signal toward increased mortality, the findings suggest that the theoretical physiological benefits of prophylactic mechanical unloading are likely offset by other procedural factors in the setting of stable high-risk revascularization.

References

1. Schäfer A, Alasnag M, Giacoppo D, et al. High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2024. doi:10.4244/eij-d-23-01100

2. Ryan MJ, Ezad S, Webb I, et al. Percutaneous Left Ventricular Unloading During High-Risk Coronary Intervention: Rationale and Design of the CHIP-BCIS3 Randomized Controlled Trial. Circulation Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.123.013367

3. Tayal R, Kalra S, Seth A, et al. Clinical expert consensus document on the use of percutaneous left ventricular assist devices during complex high-risk PCI in India using a standardised algorithm. AsiaIntervention. 2022. doi:10.4244/aij-d-22-00021

4. Chieffo A, Dudek D, Hassager C, et al. Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. EuroIntervention. 2021. doi:10.4244/eijy21m05_01

5. Chieffo A, Dudek D, Hassager C, et al. Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. European Heart Journal Acute Cardiovascular Care. 2021. doi:10.1093/ehjacc/zuab015